

Current Data Parameters
 NUC1 ¹H QNP400
 EXPC 2
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 04/05/06
 Time 18.29
 INSTRM 400J00
 PULPROG zgpg30
 TO 32768
 DELT 45
 SOLVENT CDCl3
 NS 16
 DS 2
 SWH 4708.453 Hz
 FIDRES 0.142563 Hz
 AQ 3.4062312 sec
 RG 32
 CW 1005.200 USEC
 DE 134.25 USEC
 TE 300.0 K
 D1 3.00000000 sec
 F1 10.00 USEC
 DE 134.25 USEC
 SF01 300.1315002 MHz
 NUC1 ¹H
 P1 14
 PL1 -5.00 dB

F2 - Processing parameters
 SI 32768
 SF 300.1315002 MHz
 EQ 1
 SFO 300.1315002 MHz
 DE 134.25 USEC
 TE 300.0 K
 F1 10.00 USEC
 DE 134.25 USEC
 SF01 300.1315002 MHz
 NUC1 ¹H
 P1 14
 PL1 -5.00 dB

10 MHz data parameters
 CX 50.00 cm
 CY 10.705 ppm
 F1 1040.04 Hz
 F2 1.252 DOR
 F3 175.70 Hz
 C 65826 ppm/cm
 100.70110 Hz/cm


Fig-1: ¹H-NMR spectrum of the polymer of the present invention

Fig-3: Fourier Transform Infrared (FT-IR) spectrum of the polymer of the present invention




Fig-4: TGA thermogram of the polymer of the present invention




Fig-5: DSC thermogram of the polymer of the present invention




Fig-6: Pharmacokinetic blood profile of ^{14}C -Labeled polymer of the present invention

PK blood profile of ^{14}C -labeled PNP polymer




Fig-7: Photographs of S&E Stained Rabbit ear lobe site after 48 hour of the subcutaneous injection of a 10% Dextrose solution (Control)






Fig-8: Photographs of S&E Stained Rabbit ear lobe site after 48 hour of the subcutaneous injection of an aqueous solution of Polymer of the present invention






Fig-9: Photographs of S&E Stained Rabbit's Marginal Ear Vein site after 24 hour of Intravenous Injection of a 10% Dextrose solution (Control)






Fig-10: Photographs of S&E Stained Rabbit's Marginal Ear Vein site after 24 hour of Intravenous Injection of an aqueous solution of Polymer of the present invention







Fig-11: A Typical Method For Preparation and Administration to patients in need thereof of the Nanoparticulate Pharmaceutical Composition of the Present Invention

